19 Aug, 2021 RNAi Roundtable: Lumasiran, for the Treatment of Primary Hyperoxaluria Type 1
On August 19, 2021, we hosted an online RNAi Roundtable to review the progress with lumasiran, for the treatment of primary hyperoxaluria type 1.
Jerome Valkenburg, MS, MScBA
Sr. Director & Program Lead, Lumasiran
Jeffrey M. Saland, M.D., MSCR
Professor, Icahn School of Medicine at Mount Sinai
John Gansner, M.D., Ph.D.
Director, Clinical Research